Promising new combo therapy targets rare leukemia
NCT ID NCT05870917
First seen Mar 09, 2026 · Last updated May 16, 2026 · Updated 9 times
Summary
This study tests a new treatment plan for people newly diagnosed with primary plasma cell leukemia, a rare and aggressive blood cancer. The approach combines standard chemotherapy drugs with two rounds of CAR T-cell therapy and a stem cell transplant. The goal is to see if this intense treatment is safe and can control the disease for as long as possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
RECRUITINGTianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.